Investor Contact: Contact Email care@lyrahealth.com. The companys current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for months following a single non-invasive, in-office administration. Delivering mental health care for diverse employee populations around the world is one of the most pressing and complex issues for employers today, and this new funding will help Lyra accelerate our plans to deliver comprehensive, global solutions.. Lyra delivers mental health for employees and family members at leading multinational companies, including eBay; Genentech, a member of the Roche Group; Uber; and VCA Animal Hospitals. But it was the Covid-19 pandemic and collective psychological fallout that finally mainstreamed mental health. Investors Security Type; CASTLIGHT HEALTH, INC. . Email; Facebook; . The World Health Organization estimates that the loss in productivity due to depression and anxiety alone costs the global economy $1 trillion each year. tyler.gagnon@canalecomm.com, million adult CRS patients in China alone, we believe LYR-210 has the potential to address a significant unmet medical need and meaningfully improve the standard of care for patients in Asia., Internet Explorer presents a security risk. Lyra is transforming mental health care using intelligent matching technology, concierge support, and an innovative digital platform to deliver a frictionless experience for members, providers, and employers. Theres also concern that the hyper focus on technology and virtual care is like putting lipstick on a pig. Celebrity endorsements, like Olympic swimmer Michael Phelps campaign with virtual therapy startup Talkspace, started to chip away at the long standing stigma, while mindfulness apps like Calm offered meditation sessions at the click of a button. Funding, Valuation & Revenue. from 8 AM - 9 PM ET. Chris Metinko. As part of the agreement, LianBio will also have the first right to obtain development and commercial rights in the licensed territories to Lyras LYR-220, an anti-inflammatory, intra-nasal, drug matrix in development for the treatment of CRS patients who have undergone a prior sinus surgery but continue to have persistent disease. Lyras XTreo platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. Lyra helps companies improve access to effective, high-quality mental health care for their employees. We are delighted to enter into this strategic alliance with LianBio to expand the global reach of LYR-210 for millions of CRS patients who need new and innovative treatment alternatives to surgery, said Maria Palasis, Ph.D., CEO of Lyra. Dragoneer has a history of partnering with management teams growing exceptional companies characterized by sustainable differentiation and superior economic models. Lyra Health's latest funding round was a Series G for $235M on January 19, 2022. The LianBio team has deep expertise in drug development and is well positioned to successfully commercialize LYR-210 in these Asian territories.
Lovely Dreams Perfume, Westerville Ohio News, Articles L